Key facts
- This page summarizes Donald J. Kellerman's Form 4 filing for Zosano Pharma Corp.
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 01 Apr 2022, 21:08.
Donald J. Kellerman - 31 Mar 2022 Form 4 Insider Report for Zosano Pharma Corp
- Reporting relationship
- VP, Clinical Dev & Med Affairs
- Issuer ticker
- N/A
- Reported as of
- 31 Mar 2022
- Net transaction value
- -$842
- SEC form
- 4
- Accepted by SEC
- 01 Apr 2022, 21:08:14 UTC
- Prior SEC filing
- 19 Oct 2021
- Source filing
- View source filing
- Reporting owner signature
- /s/ Steven Lo, Attorney-in-Fact for Donald J. Kellerman
Source evidence
Original filing metadata and source links for verification.
4 source fields
Reporting owner
1 detail
Key filing fact
Donald J. Kellerman filed Form 4 for Zosano Pharma Corp on 01 Apr 2022.
Change
- Previous filing in this sequence was filed on 19 Oct 2021.
- Current net transaction value: -$842.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
ZSAN
transaction
Common Stock
Sale
- Transaction value
- $842
- Shares
- -4,006
- Change %
- -6.6%
- Price
- $0.2101*
- Shares after
- 56,331
- Date
- 31 Mar 2022
- Ownership
- Direct
- Footnotes
- F1
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 1 footnote
Footnote F1
The shares were sold solely to satisfy tax or other government withholding obligations in connection with the vesting of shares subject to restricted stock units of the Issuer.